Sheng Jie, Zhang Wei-yuan
Department of Gynecology, Beijing Obstetrics & Gynecology Hospital, Capital Medical University, Beijing 100026, China.
Zhonghua Yi Xue Za Zhi. 2010 Oct 12;90(37):2611-5.
To identify the molecular biomarkers for cervical cancer in peripheral blood lymphocytes by oligonucleotide microarrays.
Human genome oligonucleotide microarray analysis included 4 early-stage cervical cancer patients and 3 controls. The selected genes from the microarray analysis were validated in additional 20 early-stage cervical cancer patients and 15 controls by real-time reverse-transcription polymerase chain reaction (RT-PCR).
Genes identified by gene selection program were expressed differently in the blood samples of early-stage cervical cancer from those of healthy controls. To validate the gene expression data, 5 genes were analyzed by real-time RT-PCR. In three of 5 identified genes, tenascin-c, nucleolin, and enolase 2 (ENO2) showed a significant up-regulation in blood samples of early-stage cervical cancer patients versus that of the controls.
The up-regulation of tenascin-c, nucleolin and ENO2 in peripheral blood may be used to identify novel blood biomarkers for detecting cervical cancer in a clinically accessible surrogate tissue. Thus it may offer a possibility of developing a non-invasive and predictive diagnostic tool for the disease.
通过寡核苷酸微阵列鉴定外周血淋巴细胞中宫颈癌的分子生物标志物。
人类基因组寡核苷酸微阵列分析纳入4例早期宫颈癌患者和3例对照。通过实时逆转录聚合酶链反应（RT-PCR）在另外20例早期宫颈癌患者和15例对照中验证从微阵列分析中选择的基因。
通过基因选择程序鉴定的基因在早期宫颈癌血样中的表达与健康对照不同。为验证基因表达数据，通过实时RT-PCR分析了5个基因。在5个鉴定出的基因中的3个，腱生蛋白-c、核仁素和烯醇化酶2（ENO2）在早期宫颈癌患者血样中相对于对照显示出显著上调。
外周血中腱生蛋白-c、核仁素和ENO2的上调可用于在临床上可获取的替代组织中鉴定用于检测宫颈癌的新型血液生物标志物。因此，这可能为开发该疾病的非侵入性和预测性诊断工具提供可能性。
